RADAR-CNS paves the way for use of remote measurement technology to manage depression, multiple sclerosis and epilepsy
The results of the six-year long Innovative Medicines Initiative (IMI) funded RADAR-CNS programme have provided
Sin categoría
A tool to access & validate knowledge encompassing all of the latest information pertaining to Alzheimer’s disease
The Biomedical Knowledge Miner (BiK>Mi) has been developed as part of the Innovative Medicines Initative’s
New research shows that severe depression does not affect engagement with RMT
Researchers from RADAR-CNS have analysed data from 547 participants diagnosed with severe depression and found
Spotlight on early-career researchers: a Neuronet interview with María Arroyo-Araujo
In this Neuronet spotlight on early-career researcher interview, we speak with María Arroyo-Araujo, who currently
AMYPAD announces end of recruitment in the Prognostic and Natural History Study
On 11 May, the members of the Amyloid Imaging to Prevent Alzheimer’s Disease (AMYPAD) project
The Neuronet Coordination and Support Action releases updated Decision Tool for engagement with Regulatory and Health Technology Assessment bodies
Madrid, 9 May 2022 – Today, the members of the Neuronet (Efficiently Networking European Neurodegeneration
AMYPAD hosts a disclosure biomarker symposium
On 1 April, the Amyloid imaging to prevent Alzheimer’s disease (AMYPAD) project held an online
Missed the Parkinson’s Research in Ireland event? Videos are now available!
The third annual Parkinson’s Research in Ireland talk series was held on March 31st and
RADAR-CNS webinar focusses on engagement with remote measurement technology in Major Depressive Disorder
The fourth RADAR-CNS webinar will present on participation and retention in a long-term study of
New partnership between AMYPAD and ADDI powers global open access to Alzheimer’s disease imaging data
A common sign of Alzheimer’s disease are deposits of a protein called beta amyloid. The